{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:58:08Z","timestamp":1790827088784,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006364","name":"French National Cancer Institute","doi-asserted-by":"publisher","award":["2019-1-PL SHS-01-IGR-1"],"award-info":[{"award-number":["2019-1-PL SHS-01-IGR-1"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Open Science"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.euros.2026.08.005","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:40:09Z","timestamp":1788543609000},"page":"28-35","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Longitudinal Economic Burden for Non\u2013Muscle-Invasive Bladder Cancer by EAU Progression Risk Groups Using the Prospective Multicenter COBLAnCE Cohort Linked to the French National Healthcare System Database"],"prefix":"10.1016","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2235-0012","authenticated-orcid":false,"given":"Ald\u00e9ric M.","family":"Fraslin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Benhamou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Lebret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"Neuzillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Droupy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gr\u00e9goire","family":"Poinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitri","family":"Vordos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Guy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautier","family":"Marcq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Coloby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Monges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"M\u00e9jean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Potiron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Descotes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Eschwege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Loison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mentine","family":"Krucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Mangin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Radvanyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Allory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Karimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Bonastre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euros.2026.08.005_b0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euros.2026.08.005_b0010","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.08.005_b0015","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.08.005_b0020","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.3050","article-title":"Management, surveillance patterns, and costs associated with low-grade papillary stage Ta Non-muscle-invasive bladder cancer among older adults, 2004\u20132013","volume":"5","author":"Bree","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.euros.2026.08.005_b0025","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.eururo.2024.12.002","article-title":"The financial burden of localized and metastatic bladder cancer","volume":"87","author":"Scilipoti","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.08.005_b0030","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.eururo.2015.10.024","article-title":"Economic burden of bladder cancer across the European Union","volume":"69","author":"Leal","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.08.005_b0035","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2217\/fon-2019-0817","article-title":"KEYNOTE-676: phase III study of BCG and pembrolizumab for persistent\/recurrent high-risk NMIBC","volume":"16","author":"Kamat","year":"2020","journal-title":"Future Oncol"},{"key":"10.1016\/j.euros.2026.08.005_b0040","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1016\/S0140-6736(25)01897-5","article-title":"Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial","volume":"406","author":"De Santis","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.euros.2026.08.005_b0045","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1038\/s41591-025-03738-z","article-title":"Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial","volume":"31","author":"Shore","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.euros.2026.08.005_b0050","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1186\/s12885-016-2877-x","article-title":"A prospective multicenter study on bladder cancer: the COBLAnCE cohort","volume":"16","author":"Benhamou","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.euros.2026.08.005_b0055","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-075942","article-title":"Cohort profile: COBLAnCE: a French prospective cohort to study prognostic and predictive factors in bladder cancer and to generate real-world data on treatment patterns, resource use and quality of life","volume":"13","author":"Lebret","year":"2023","journal-title":"BMJ Open"},{"issue":"Suppl. 4","key":"10.1016\/j.euros.2026.08.005_b0060","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1016\/j.respe.2017.05.004","article-title":"Value of a national administrative database to guide public decisions: from the syst\u00e8me national d\u2019information interr\u00e9gimes de l\u2019assurance maladie (SNIIRAM) to the syst\u00e8me national des donn\u00e9es de sant\u00e9 (SNDS) in France","volume":"65","author":"Tuppin","year":"2017","journal-title":"Rev Epidemiol Sante Publique"},{"key":"10.1016\/j.euros.2026.08.005_b0065","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European Association of Urology (EAU) prognostic factor risk groups for non\u2013muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC guidelines panel","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.08.005_b0070","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/sim.4067","article-title":"Multiple imputation using chained equations: issues and guidance for practice","volume":"30","author":"White","year":"2011","journal-title":"Stat Med"},{"key":"10.1016\/j.euros.2026.08.005_b0075","first-page":"1","article-title":"Mice: multivariate Imputation by Chained Equations in R","volume":"45","author":"van Buuren","year":"2011","journal-title":"J Stat Softw"},{"key":"10.1016\/j.euros.2026.08.005_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2025.102344","article-title":"Incidence of bladder cancer, healthcare pathways, and economic burden: a real-world observational study from the French national healthcare system database","volume":"23","author":"Fraslin","year":"2025","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euros.2026.08.005_b0085","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.eururo.2014.01.006","article-title":"The economics of bladder cancer: costs and considerations of caring for this disease","volume":"66","author":"Svatek","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.08.005_b0090","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s40273-023-01273-8","article-title":"Cost-effectiveness and economic impact of bladder cancer management: an updated review of the literature","volume":"41","author":"Joyce","year":"2023","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.euros.2026.08.005_b0095","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.3800","article-title":"Estimated costs and long-term outcomes of patients with high-risk non\u2013muscle-invasive bladder cancer treated with Bacillus Calmette-Gu\u00e9rin in the Veterans Affairs health system","volume":"4","author":"Williams","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.euros.2026.08.005_b0100","doi-asserted-by":"crossref","first-page":"39.e11","DOI":"10.1016\/j.urolonc.2019.10.016","article-title":"Longitudinal patterns of cost and utilization of medicare beneficiaries with bladder cancer","volume":"38","author":"Sloan","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euros.2026.08.005_b0105","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2022.1229","article-title":"Comparison of cancer-related spending and mortality rates in the US vs 21 high-income countries","volume":"3","author":"Chow","year":"2022","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.euros.2026.08.005_b0110","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/MOU.0000000000001218","article-title":"Reducing financial toxicity in bladder cancer care","volume":"34","author":"Kurnot","year":"2024","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.euros.2026.08.005_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcpo.2022.100326","article-title":"Socio-economic burden of disease: survivorship costs for bladder cancer","volume":"32","author":"Michaeli","year":"2022","journal-title":"J Cancer Policy"},{"key":"10.1016\/j.euros.2026.08.005_b0120","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/13696998.2023.2189860","article-title":"Evaluating the cost-utility of intravesical Bacillus Calmette-Gu\u00e9rin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK","volume":"26","author":"Grabe-Heyne","year":"2023","journal-title":"J Med Econ"},{"key":"10.1016\/j.euros.2026.08.005_b0125","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1464-410X.2009.08716.x","article-title":"Treatment costs of prostate cancer in the first year after diagnosis: a short-term cost of illness study for France, Germany, Italy, Spain and the UK","volume":"105","author":"Fourcade","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.euros.2026.08.005_b0130","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/bju.15941","article-title":"A prospective descriptive 1-year study in France of all BCG therapy dispensations for non-muscle-invasive bladder cancer","volume":"131","author":"Neuzillet","year":"2023","journal-title":"BJU Int"}],"container-title":["European Urology Open Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168326011791?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168326011791?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:27:42Z","timestamp":1790825262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666168326011791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":26,"alternative-id":["S2666168326011791"],"URL":"https:\/\/doi.org\/10.1016\/j.euros.2026.08.005","relation":{},"ISSN":["2666-1683"],"issn-type":[{"value":"2666-1683","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Longitudinal Economic Burden for Non\u2013Muscle-Invasive Bladder Cancer by EAU Progression Risk Groups Using the Prospective Multicenter COBLAnCE Cohort Linked to the French National Healthcare System Database","name":"articletitle","label":"Article Title"},{"value":"European Urology Open Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euros.2026.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}